Methicillin-Resistant Staphylococcus Aureus | TreatmentTrends | US | 2015
Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important Gram-positive pathogen in both the hospital and outpatient settings. The recent FDA approvals of oritavancin (The Medicine’s Company’s Orbactiv), dalbavancin (Allergan’s Dalvance), and tedizolid (Merck’s Sivextro) highlight the increasing availability of treatment options for MRSA infections, making this hospital market segment highly competitive. It will therefore be critically important for manufacturers to position their products based on differentiating attributes in order to maximize uptake in the high-value hospital market segment.
This report focuses on the treatment of inpatients with MRSA infections and analyzes the hospital prescribing practices for infections due to MRSA and other clinically important Gram-positive (GP) pathogens. The report additionally explores physician prescribing behavior and preferences in the outpatient parenteral antibiotic therapy (OPAT) setting—a key segment of the MRSA infections market. Finally, this study evaluates the advantages and disadvantages of currently available and emerging therapies to identify areas for product positioning and differentiation.
